Data from small cell neuroendocrine carcinoma of the cervix: FIGO 2018 staging is more accurate than FIGO 2009

Abstract

Objective To compare the prognostic value of International Federation of Gynecology and Obstetrics (FIGO) 2009 and 2018 staging systems in surgical patients with small cell neuroendocrine carcinoma of the cervix (SCNEC). Methods We re-staged 64 surgical IB–IIA (FIGO 2009) SCNEC patients according to the FIGO 2018 system and refined stage IIIC of FIGO 2018 based on tumor local invasion. The prognostic factors were analyzed, and the advantages of FIGO 2018 were compared with 2009. Results The 5-year overall survival rate (OS) was 78.5% for stage I and 22.2% for stage II (FIGO 2009). In FIGO 2018, there was no difference between stage I and II, and the 5-year OS was 74.1%, 60.2%, and 0% for stage I/II, IIIC1, and IIIC2. After combining stage IIIC with the local invasion stage (T1 was limited to the cervix and vagina; T2 involved the parametrium; T3 involved the pelvic or abdominal cavity), the 5-year OS for stage IIICT1, IIICT2, and IIICT3 was 83.3%, 30.0%, and 0%, respectively. Conclusions For stage II SCNEC patients, FIGO 2009 underestimated the prognosis, while FIGO 2018 was more accurate. For stage IIIC, FIGO 2018 might be more individualized and accurate after combining stage IIIC with tumor local invasion.

The impact of neo/adjuvant treatment choices on prognosis for surgically treated small-cell neuroendocrine carcinoma of the cervix

“…The optimal therapeutic strategy for SCNCC remains a subject of ongoing debate. Treatment for small cell neuroendocrine carcinoma of the cervix should be more aggressive and adequate even for early-stage disease [20]. Surgical treatment is a very important therapeutic measure.…”

Prognostic model for survival in patients with neuroendocrine carcinomas of the cervix: SEER database analysis and a single-center retrospective study

“…Chen et al analyzed clinicopathological factors in 290 patients with SCNECC from the SEER database and compared their 5-year overall survival rates to those with common subtypes of cervical cancers [4], but the study failed to extend to other cohorts. Meanwhile, several recent studies based on single-center retrospective investigations revealed that cycles of chemotherapy, chemotherapy regimens, and FIGO 2018 staging system served as prognostic factors for patients with NECC [13][14][15], while validated prediction models have not been established yet. Fortunately, during the past decade, the survival rate of cervical cancer has increased [16], and novel models to better predict the survival of patients with cancer, such as nomogram, have been evolving [17].…”